viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals' gets access to EU market for ArtemiC to escalate EU exposure and sales

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, FRA:H5O, ASX:MXC) (LSE:MXC, OTC:MGCLF, FRA:H5O, ASX:MXC) Roby Zomer joins Proactive London's Katie Pilbeam to explain how the approval for sale in the European Union of ArtemiC will impact company. 

The firm has been granted a certificate of free sale in Germany which Zomer explains will open up doors to sales in the EU and other international markets.

He says the Free Trade Certificate for ArtemiC Rescue and the ArtemiC product line in Germany, is a significant step forward for MGC Pharma as it opens the EU to the marketing and sale of one of the company's leading products.

Quick facts: MGC Pharmaceuticals Ltd


Price: 3.15 GBX

Market Cap: £75.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

1 week, 5 days ago

2 min read